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Tumor Necrosis Factor –Induced Interleukin-18
Bioactivity in Rheumatoid Arthritis Synovial Fibroblasts
by Induction of Interleukin-18 Binding Protein a
Role of the Nuclear Interferon Regulatory Factor 1–NF-B–c-Jun Complex
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Objective. To examine the role of interferon reg-
ulatory factor 1 (IRF-1) in tumor necrosis factor 
(TNF)–induced interleukin-18 binding protein a (IL-
18BPa) expression in rheumatoid arthritis synovial
fibroblasts (RASFs).
Methods. TNF-induced IRF-1 expression was
assessed by real-time quantitative polymerase chain
reaction and Western blotting. The effect of TNF on
IRF-1 was assessed using nuclear and cytoplasmic
extracts, Western blots, and immunofluorescence.
Chemical inhibitors of NF-B or MAP kinases were
used to analyze the signaling pathways of TNF-
induced IRF-1 expression and IRF-1 nuclear transloca-
tion. Control and IRF-1 small interfering RNA (siRNA)
were used to analyze the effect of IRF-1 down-regulation
on TNF-induced IL-18BP expression. IL-18BPa ex-
pression was assessed by enzyme-linked immunosor-
bent assay, and IL-18 was assessed at the transcription
and bioactivity levels using KG-1 cells.
Results. TNF induced RASF IRF-1 expression at
the messenger RNA and protein levels, with a maximal
effect at 2 hours (P < 0.05; n > 3). Furthermore, TNF
induced nuclear translocation of IRF-1, with maximal
translocation at 2 hours (6 fold-induction) (P < 0.05;
n  4). Blocking of the NF-B or JNK-2 pathways
reduced TNF-induced IRF-1 nuclear translocation by
35% and 50%, respectively (P < 0.05; n > 4). Using
siRNA to knock down IRF-1, we observed reduced
IL-18BPa expression. Additionally, IL-18 bioactivity
was higher when siRNA was used to knock down IRF-1
expression.
Conclusion. These results show that IRF-1 is a
key regulator of IL-18BPa expression and IL-18 bioac-
tivity in RASFs. Regulation of IRF-1 will be a new
therapeutic target in RA.
Rheumatoid arthritis (RA) is the most common
chronic articular inflammatory disease involving joint
destruction. The inflamed RA synovial tissue is charac-
terized by a massive infiltration of lymphocytes and
macrophages and proliferation of synovial fibroblasts
(SFs). Interleukin-18 (IL-18) is considered to be a key
cytokine in the pathogenesis of RA (1). Initially de-
scribed as an interferon- (IFN)–inducing factor (2),
IL-18 is a member of the IL-1 family (3), which is
important as a regulator of innate and acquired immune
responses. IL-18 promotes the release of Th1 cytokines
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by T cells as well as Th1 cell differentiation (4), influ-
ences the cytotoxic activity of natural killer cells through
up-regulation of Fas ligand (2,4–9), and promotes an-
giogenesis (10–13). It is synthesized as a precursor,
proIL-18, which is cleaved by the IL-1–converting
enzyme (caspase 1), resulting in the active 18.3-kd
mature protein (14,15). IL-18 expression has been de-
tected in antigen-presenting cells such as activatedmacro-
phages, Kupffer cells, dendritic cells, Langerhans cells,
and epidermal cells, as well as in articular chondrocytes,
osteoblasts, and activated SFs (1,2,16–20).
Compared with other proinflammatory cyto-
kines, IL-18 is regulated in a unique way. Constitutive
levels of IL-18 messenger RNA (mRNA) and protein
are present in unstimulated human and murine cells and
in the tissues of untreated normal mice (21,22). In
unstimulated cells or tissues, IL-18 is primarily present
in the precursor form, which requires conversion by
caspase 1 to the mature and bioactive molecule
(14,15,18,21). The other way to regulate IL-18 bioactiv-
ity is via its natural inhibitor, IL-18 binding protein
(IL-18BP). In humans, 4 isoforms of IL-18BP (isoforms
a, b, c, and d) have been described and are produced as
a result of alternative splicing. Only isoforms a and c are
able to neutralize IL-18 bioactivity. IL-18BPa is the
major constitutively secreted splicing variant, with the
highest binding affinity for IL-18, and thereby acts as a
soluble decoy receptor (23). IL-18 bioactivity is17-fold
lower than its total protein level, suggesting that inhibi-
tion of IL-18 bioactivity can be attained by increasing the
level of IL-18BPa (16).
As we recently suggested, inhibition of IL-18
bioactivity can be attained by increasing the level of
IL-1BPa (20). Interferon regulatory factor 1 (IRF-1) is a
transcription factor that was initially described to be
strongly induced by IFN and to bind to IFN-stimulated
response elements within promoters, thereby activating
transcription (24). It was recently shown to be a key
regulator of IL-18BP expression (25). The IL-18BP
promoter contains an IRF-1 binding site (25). Indeed,
the expression of IL-1BP was reduced or undetectable in
IRF-1–knockout mice (25–27). In the same mice, IL-18
expression was unaffected (27), suggesting an increase in
IL-18 bioactivity. Recently, we demonstrated that tumor
necrosis factor  (TNF) was able to induce both IL-18
and IL-18BP expression by RASFs, and that blocking of
the ERK signaling pathway reduced TNF-induced
IL-18 bioactivity by inhibiting IL-18 expression (20).
Here, we examined the role of IRF-1 in TNF-induced
IL-18BPa expression.
MATERIALS AND METHODS
Cytokines and culture of human RASFs. TNF was
purchased from R&D Systems. Fibroblasts were isolated,
according to an institutional review board–approved protocol,
from synovium obtained from RA patients who had undergone
total joint replacement or synovectomy and were processed as
described previously (20,28,29). RASFs were grown in RPMI
1640 with 10% fetal bovine serum supplementation. All of the
experiments were performed in serum-free media.
RNA extraction and real-time quantitative polymerase
chain reaction (qPCR). RNA was isolated from RASFs using
RNeasy Mini kits in conjunction with QIAshredders, according
to the manufacturer’s protocol (Qiagen), as described previ-
ously (20,28). Following isolation, RNA was quantified and
checked for purity by spectrophotometry (NanoDrop Tech-
nologies). Complementary DNA (cDNA) was then prepared
using a Reverse-iT MAX 1st Strand Synthesis Kit (ABgene),
as described previously (20,28). Quantitative PCR was per-
formed using Platinum SYBR Green qPCR SuperMix-UDG
(Invitrogen) according to the manufacturer’s protocol, with
the following specific primer sequences: for IRF-1, forward
5-AGCCAACATGCCCATCACTCGG-3, reverse 5-
TGCTACGGTGCACAGGGAATGG-3 (30); for IL-18,
forward 5-CTTGAATCTAAATTATCAGTC-3, reverse 5-
GAAGATTCAAATTGCATCTTAT-3 (20); and for -actin,
forward 5-GTCAGGCAGCTCGTAGCTCT-3, reverse 5-
CCATGTACGTTGCTATCCA-3 (20,28).
Diluted cDNA was briefly mixed with Platinum SYBR
Green qPCR SuperMix-UDG and forward and reverse prim-
ers specific for each gene (0.2 M final concentration) and was
incubated under the following conditions: 50°C for 2 minutes,
95°C for 2 minutes, and 40 cycles of 95°C for 30 seconds, 55°C
for 30 seconds, and 68°C for 30 seconds using an Eppendorf
Mastercycler ep realpex thermal cycler. All samples were run
in duplicate and analyzed using Eppendorf software. For
quantification, the relative abundance of each gene was nor-
malized to -actin.
Cell lysis and Western blotting. To study the effect of
TNF on IRF-1 production, RASFs were incubated with
TNF (20 ng/ml) in serum-free RPMI 1640, and assessed at
several time points. Cells were lysed in cell lysis buffer con-
taining 1 mM phenylmethylsulfonyl fluoride (PMSF) and pro-
tease inhibitors (Thermo Scientific), as previously described
(29). Protein was measured using a BCA Protein Assay kit
(Pierce). Equal amounts of protein (15 g) were loaded and
separatedbysodiumdodecyl sulfate–polyacrylamidegelelectro-
phoresis and transferred onto nitrocellulose membranes (Bio-
Rad). Nitrocellulose membranes were blocked with 5% nonfat
milk in Tris buffered saline–Tween 20 (TBST) for 60 minutes
at room temperature. Blots were incubated overnight at 4°C
with optimally diluted specific primary antibody in TBST
containing 5% nonfat milk. A mouse anti-human IRF-1 mono-
clonal antibody (Santa Cruz Biotechnology) was used as the
primary antibody. Blots were washed 3 times and incubated in
horseradish peroxidase–conjugated antibody (1:1,000 dilution)
for 1 hour at room temperature. Protein bands were detected
using enhanced chemiluminescence (Pierce) in accordance
with the manufacturer’s instructions. After stripping, blots
were probed again using a rabbit anti–-actin polyclonal
antibody. Blots were scanned and analyzed for band intensities
using UN-SCAN-IT version 5.1 software (Silk Scientific).
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Nuclear and cytoplasmic extracts. RASFs (2  106/
well) were grown to confluence in 6-cm dishes and treated with
TNF (20 ng/ml) with or without preincubation with inhibi-
tors. Cytoplasmic and nuclear fractions were prepared as
previously described (31). Upon termination of the reaction,
cells were washed twice with ice-cold phosphate buffered
saline (PBS) (pH 7.4), scraped, collected in Eppendorf tubes,
and centrifuged at 1,500g for 5 minutes at 4°C. The pellet
obtained was suspended in 300 l of buffer A (10 mM HEPES
buffered saline [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol [DTT], and 0.5 mM PMSF), gently
mixed, and placed on ice for 15 minutes. Twenty-five micro-
liters of cold 10% Nonidet P40 was added to individual
samples, and the samples were vortexed and centrifuged at
14,000g for 1 minute. The supernatant (cytoplasmic fraction)
was collected, and the nuclear pellet obtained was suspended
in 60 l of buffer C (20 mM HEPES buffered saline [pH 7.9],
0.4M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM
PMSF) and rocked for 45 minutes at 4°C. Samples were
centrifuged for 15 minutes at 14,000g at 4°C. The supernatant
(nuclear fraction) was collected and stored at 80°C. Nuclear
and cytoplasmic cell lysates (15 g) were used for the detection
of IRF-1 by Western blotting. After stripping, blots were
probed successively with a rabbit anti–histone H3 polyclonal
antibody (Abcam) and anti–-actin antibodies to check the
purity of both fractions.
Immunofluorescence staining. RASFs were plated at
10,000 cells/well in 8-well Lab-Tek chamber slides. After
overnight serum starvation, cells were left untreated or were
stimulated with TNF (20 ng/ml) for 2 hours. Cells were
washed with PBS, fixed with 4% formalin for 30 minutes at
room temperature, washed again with PBS, and fixed with
ice-cold methanol for 5 minutes. Blocking was performed by
adding 5% serum in PBS for 1 hour at room temperature.
IRF-1 primary antibody (5 g/ml) in blocking buffer was
added for 1 hour at room temperature. Following washing,
Alexa Fluor–conjugated goat anti-rabbit antibody (10 g/ml)
was added for 1 hour at room temperature. Cells were washed
with PBS, and DAPI nuclear stain (1:2,000 dilution; Invitro-
gen) was added for 5 minutes. Slides were dehydrated,
mounted, and coverslipped. Images were obtained using an
Olympus FluoView 500 confocal fluorescence microscope. A
60 objective was used, and 0.5-m optical sections were
obtained.
Chemical inhibitors. To study the signaling mechanism
of IRF-1 expression and nuclear translocation by TNF,
RASFs were incubated with MAPK inhibitors (ERK-1/2
[PD98059], p38 [SB202190], and JNK-2 [SP600125]) or with
an NF-B inhibitor (pyrrolidine dithiocarbamate [PDTC]) for
1 hour, followed by stimulation with TNF (20 ng/ml). The
concentration of the inhibitors (10 M for ERK-1/2, p38, and
JNK-2; 200 M for PDTC) was based on our previous studies
(20,28). At these concentrations, RASF viability was not
affected (32). All inhibitors were purchased from Calbiochem.
Immunoprecipitation. For immunoprecipitation, nu-
clear fractions containing equal amounts of protein were
incubated with rabbit anti-human phosphorylated NF-B p65,
rabbit anti-human phosphorylated c-Jun, or rabbit IgG control
overnight at 4°C, using the Pierce Classic Immunoprecipitation
kit according to the protocol described by the manufacturer.
Equal amounts were then loaded and run on Western blots to
detect IRF-1. Next, the blots were stripped and reprobed with
the antibodies used for immunoprecipitation.
Transfection studies. To analyze the effect of IRF-1
knockdown, we used a transfection approach with small inter-
fering RNA (siRNA). RASFs were maintained in RPMI 1640
with 10% fetal bovine serum and plated in 6-well plates to grow
to 60% confluence. Then, they were transfected with either
100 nM control siRNA (Invitrogen) or IRF-1 siRNA (Dhar-
macon) using TransIT-TKO reagent (Mirus). After 48 hours,
the cells were serum starved in RPMI 1640 overnight and then
stimulated with TNF (20 ng/ml) for 2 hours or 48 hours.
Conditioned media, cell lysates, and mRNA were processed as
described above.
IL-18 bioactivity. The biologic activity of IL-18 was
measured by using human myelomonocytic KG-1 cells, as
previously described (20). KG-1 cells (3 106 cells/ml; 100 l),
with or without mouse monoclonal anti–IL-18 antibody at
1 g/ml (R&D Systems), were dispensed into the wells of
96-well Falcon microtiter plates (Becton Dickinson). Next,
100 l of samples or recombinant human IL-18 standards was
added to each well. The plates were incubated, and culture
supernatants were harvested 24 hours later. The IFN concen-
tration in this media was determined by enzyme-linked immu-
nosorbent assay (Invitrogen). IL-18 bioactivity was determined
based on the difference in IFN levels between cultures with
and those without mouse anti–IL-18 monoclonal antibody.
Statistical analysis. Student’s t-tests were performed
to calculate statistical differences between the means of the
different variables. Two-tailed P values less than 0.05 were
considered significant.
RESULTS
Time-dependent TNF-induced IRF-1 in RASFs.
To examine the effect of TNF (20 ng/ml) on IRF-1
production, we investigated its effects at the mRNA and
protein levels. TNF stimulation of RASFs was per-
formed for various amounts of time, up to 48 hours.
IRF-1 was induced by TNF at the mRNA level, with a
maximal effect at 2 hours (P  0.05; n  3) (Figure 1A).
Similar results were observed at the protein level (P 
0.05; n  6) (Figure 1B). The results suggested that
TNF induced IRF-1, with a significant effect observed
after 2 hours of stimulation at the transcription and
protein levels.
MAPK and NF-B signaling pathway–
independence of TNF-induced IRF-1 expression by
RASFs. To identify the signaling events that are critical
for TNF-induced IRF-1 expression, RASFs were incu-
bated with chemical signaling inhibitors for 1 hour,
followed by stimulation with TNF (20 ng/ml) for 2
hours. The results of this study showed that none of the
inhibitors (NF-B [PDTC], ERK-1/2 [PD98059], p38
[SB202190], or JNK-2 [SP600125]) significantly inhib-
ited TNF-induced IRF-1 expression at either the tran-
scription level (Figure 2A) or the protein level (Figure
2B). These results indicated that TNF induction of
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Figure 1. Up-regulation of interferon regulatory factor 1 (IRF-1)
in rheumatoid arthritis synovial fibroblasts (RASFs) exposed to
tumor necrosis factor  (TNF). RASFs (2  105/well; 2 ml/well)
were stimulated with TNF in serum-free media for 0–48 hours.
IRF-1 expression was assessed at the mRNA level (A) and at the
protein level (B). Bars show the mean  SEM.   P  0.05.
NS  nonstimulated. n  number of donors and independent ex-
periments.
Figure 2. No effect of signaling inhibition on TNF-induced IRF-1
levels in RASFs. RASFs were preincubated with different inhibitors
for 1 hour, followed by stimulation with TNF for 2 hours. IRF-1
expression was assessed at the mRNA level (A) and at the protein level
(B). Bars show the mean  SEM. PDTC  pyrrolidine dithiocarbam-
ate (see Figure 1 for other definitions).
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Figure 3. Nuclear translocation of IRF-1 in RASFs exposed to TNF. A, RASFs (2  106/well) were stimulated with TNF for 2, 4, or 8 hours in
serum-free media. The cytoplasmic and nuclear fractions were prepared as described in Materials and Methods. Blots were probed successively for IRF-1,
histone H3, and -actin. Bars show the mean SEM.  P 0.05. B, Localization of IgG control and IRF-1 on RASFs with or without stimulation with
TNF (20 ng/ml for 2 hours) was examined by immunofluorescence and confocal microscopy (60 objective and 0.5-m optical sections). Arrows indicate
IRF-1, which was predominantly expressed in the cytoplasm without TNF stimulation (middle) and was observed in the nucleus after 2 hours of TNF
stimulation (right). The images are representative of 4 independent experiments. OD  optical density (see Figure 1 for other definitions).
Figure 4. TNF-induced IRF-1 nuclear translocation. A, RASFs were preincubated for 2 hours with pyrrolidine dithiocarbamate (PDTC;
200 M), PD98059 (10 M), SB202190 (10 M), or SP600125 (10 M) and then stimulated for 2 hours with TNF (20 ng/ml). IRF-1 nuclear
translocation was determined by Western blotting, using the nuclear extract from RASFs. Bars show the mean  SEM. B, RASFs were
preincubated for 2 hours with PDTC (200 M) or PD98059 (10 M) and then stimulated with TNF (20 ng/ml) for 2 hours. Localization of
IRF-1 on RASFs with or without TNF stimulation was examined using immunofluorescence and confocal microscopy. After 2 hours of
stimulation with TNF, IRF-1 (arrows) was expressed in the nucleus (left). After preincubation with PDTC, IRF-1 expression was more
pronounced in the cytoplasm (middle), whereas preincubation with PD98059 did not affect the location of IRF-1 in the nucleus. The images
are representative of 4 independent experiments. See Figure 1 for other definitions.
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IRF-1 in RASFs is not regulated by the MAPK pathway
or the NF-B pathway.
Time-dependent TNF-induced IRF-1 nuclear
translocation in RASFs. Because we hypothesized that
IRF-1 is the key regulator of TNF-induced IL-18BP in
RASFs, we investigated IRF-1 nuclear translocation
induced by TNF (20 ng/ml) at 2, 4, and 8 hours. IRF-1
in the nuclear and cytoplasmic lysates was detected by
Western blotting after TNF stimulation. IRF-1 nuclear
translocation was induced by TNF at 2 hours, 4 hours,
and 8 hours (6.7-, 5.3-, and 5.4-fold compared with
unstimulated controls) (P  0.05; n  4) (Figure 3A).
After successive stripping, the purity of the nuclear and
cytoplasmic fractions was confirmed by probing for
anti–histone H3 and anti–-actin, respectively. We also
confirmed that an equal amount of protein was loaded in
each fraction. We then confirmed the effect of TNF on
IRF-1 nuclear translocation using dual confocal immu-
nofluorescence microscopy with anti–IRF-1 antibody
and DAPI staining. Without stimulation, IRF-1 was
predominantly detected in the cytoplasm of RASFs
(Figure 3B). After 2 hours of TNF stimulation, IRF-1
was observed predominantly in the nucleus (Figure 3B),
confirming the results observed using nuclear extracts
and Western blots.
Roles of the JNK-2 and NF-B, but not the
ERK-1/2 or p38, signaling pathways in TNF-induced
IRF-1 nuclear translocation. Because we previously
observed that NF-B and JNK-2 are critical signaling
pathways for TNF-induced expression of IL-18BP (20),
we investigated the effect of blocking these signaling
pathways on TNF-induced IRF-1 nuclear transloca-
tion. RASFs were incubated for 1 hour with chemical
inhibitors of signaling, followed by stimulation with
TNF (20 ng/ml) for 2 hours. The inhibitors of the
NF-B (PDTC) and JNK-2 (SP600125) signaling path-
ways significantly (P  0.05) repressed TNF-induced
IRF-1 nuclear translocation in RASFs (by 48% and
57%, respectively, versus no inhibition) (Figure 4A). In
contrast, the inhibitors of ERK-1/2 (PD98059) and p38
(SB202190) did not significantly inhibit TNF-induced
IRF-1 nuclear translocation. These results indicated that
induction of IRF-1 in RASFs by TNF occurs via the
NF-B and JNK-2 signaling pathways, but not via the
ERK-1/2 pathway or the p38 signaling pathway.
We then confirmed the key role of the NF-B
signaling pathway by using confocal immunofluores-
cence microscopy. With blocking of the NF-B signaling
pathway, TNF-induced expression of IRF-1 remained
predominantly in the cytoplasm (Figure 4B). Further-
more, with blocking of the ERK-1/2 signaling pathway,
TNF-induced IRF-1 was preferentially expressed in the
nucleus (Figure 4B), with expression similar to that
observed following TNF stimulation alone (Figure 4B).
This confirmed that the NF-B signaling pathway is
required for TNF-induced IRF-1 nuclear transloca-
tion.
Role of IRF-1 in forming a complex with NF-B
and c-Jun in the nucleus. To investigate whether IRF-1
forms a complex in the nucleus, we performed immuno-
precipitation with antibodies against phosphorylated
NF-B p65 or phosphorylated c-Jun, with or without
stimulation with TNF (20 ng/ml) for 2 hours. After
immunoprecipitation for phosphorylated NF-B p65,
we observed a low level of IRF-1 without stimulation,
with an increase of at least 20-fold in the presence of
TNF (Figure 5). After immunoprecipitation for phos-
phorylated c-Jun, we observed a low level of IRF-1
without stimulation, with an increase of at least 6-fold
in the presence of TNF (Figure 5). After stripping
was performed, we confirmed the specificity of immuno-
precipitation by reprobing the blots with the antibodies
used for immunoprecipitation. These results suggested
that IRF-1 binds to phosphorylated NF-B p65 and
phosphorylated c-Jun in the nucleus.
Role of blocking IRF-1 in reducing IL-18BPa
expression and increasing TNF-induced IL-18 bioac-
tivity in RASFs. To investigate the direct effect of IRF-1
on IL-18BPa production, we transfected RASFs with
control or IRF-1 siRNA for 48 hours, followed by TNF
stimulation. We first checked the knockdown efficacy by
assessing IRF-1 at the protein level after 2 hours of
TNF induction. Compared with control siRNA, IRF-1
siRNA was reduced by 80% at the protein level (P 
0.05; n  3) (Figure 6A). We then assessed IL-18BPa
expression at the protein level after 48 hours of TNF
stimulation, in the presence or absence of IRF-1 knock-
down. We observed that blocking of IRF-1 reduced
IL-18BPa by 70% at the mRNA and protein levels (P 
0.05; n  6) (Figure 6B). When TNF-induced IL-18
expression was assessed at the mRNA level, we observed
that blocking of IRF-1 had no effect on its expression
(Figure 6C). We then assessed IL-18 bioactivity in the
conditioned medium using KG-1 cells. In cells trans-
fected with IRF-1 siRNA, TNF induced almost 8-fold
higher levels of IL-18 bioactivity compared with control
siRNA (P  0.05; n  6) (Figure 6C). These results
indicated a crucial role of IRF-1 in regulating TNF-
induced IL-18 bioactivity.
Summary of the mechanism of TNF induction
of IL-18 and IL-18BPa through IRF-1 nuclear translo-
cation. The results from this study suggested that TNF
induces IL-18BP through IRF-1 nuclear translocation.
Knocking down IRF-1 reduced this induction and
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changed the balance between IL-18 and IL-18BPa by
increasing IL-18 bioactivity in RASFs (Figure 6D).
DISCUSSION
Recently, we showed that TNF induced IL-18,
IL-18BPa, and IL-18 bioactivity in RASFs (20). In
addition, blocking of the ERK-1/2 signaling pathway
decreased IL-18 bioactivity by blocking TNF-induced
IL-18 expression, without an effect on IL-18BPa expres-
sion (20). Checking critical pathways for TNF-induced
IL-18BPa expression showed that the NF-B and JNK-2
signaling pathways were relevant without affecting IL-18
expression (20), and blocking of IL-18BPa expression
would allow an increase in IL-18 bioactivity. IFN has
been described to induce IRF-1 expression and bind to
the IL-18BP promoter (25). Because IFN levels are low
in the RA joint (33), and based on these previous
observations, we hypothesized that IRF-1 is a key regu-
lator of TNF-induced IL-18 bioactivity in RASFs by
regulating IL-18BPa.
In 1989, IRF-1 was described to be induced by
type I IFN and to induce IFN-inducible genes (24).
IRF-1 was then shown to mediate IL-18BP expression
induced by IFN (25,27). Therefore, according to our
hypothesis, we first demonstrated that TNF induced
IRF-1 at the transcription and protein levels. Only a few
other cytokines besides IFN have been reported to
induce IRF-1 expression. IL-12 and IL-18, alone or in
combination, were reported to induce IRF-1 in mouse
splenocytes (26). Recently, TNF was described to
induce IL-32 through IRF-1 (34). TNF was also re-
cently described to induce IRF-1 expression in human
umbilical vein endothelial cells (HUVECs) (35),
whereas IL-1 or TNF had no effect on IRF-1 expres-
sion in human keratinocytes (36). Furthermore, lipo-
polysaccharide was also reported to induce IRF-1 ex-
pression in murine macrophages, using a microarray
approach (37). The time course of TNF-induced IRF-1
expression is in accordance with the time course previ-
ously described in murine L929 cells (24), murine macro-
phages (37), human keratinocytes (36), or HUVECs
(35). The discrepancy between the time course of
mRNA and protein expression could be explained, in
part, by posttranscription and translation regulation, as
well as the short IRF-1 half-life of 30 minutes (38),
which suggests no accumulation of IRF-1 at the protein
level.
The second step was to explore how TNF also
induced IRF-1 nuclear translocation. We observed that
IRF-1 nuclear translocation was maximal after 2 hours
of TNF stimulation. Based on our hypothesis, we
investigated the effect of blocking of the NF-B or
MAPK signaling pathways on TNF-induced IRF-1
nuclear translocation. After blocking the NF-B or
JNK-2 signaling pathway, we observed a reduction of
IRF-1 nuclear translocation, suggesting that both the
NF-B and JNK-2 signaling pathways are required for
nuclear translocation, whereas the p38 and ERK-1/2
signaling pathways are not required. Because we previ-
ously showed that the NF-B and/or JNK-2 signaling
pathways are critical for TNF-induced IL-18BPa ex-
pression (20), our data provided indirect evidence that
IRF-1 is associated with IL-18BP production.
We then demonstrated at the mRNA and protein
levels that TNF-induced IRF-1 expression was not
Figure 5. IRF-1 binds to phosphorylated NF-B p65 and phosphor-
ylated c-Jun in the nucleus after TNF stimulation. Equalized (0.75
mg) protein from the RASF nuclear fraction, with or without TNF
stimulation (20 ng/ml for 2 hours), was immunoprecipitated with
anti–phosphorylated NF-B p65 or anti–phosphorylated c-Jun anti-
bodies, and Western blotting was performed using an anti–IRF-1
antibody. After stripping, the blots were probed for phosphorylated
NF-B p65 or phosphorylated c-Jun. The results shown are represen-
tative of 2–4 assays. Bars show the mean  SEM.   P  0.05. OD 
optical density (see Figure 1 for other definitions).
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affected by blocking the NF-B or JNK-2 signaling
pathway. Thus, our results suggested that the NF-B
and/or JNK-2 signaling pathways are required for
TNF-induced IRF-1 nuclear translocation without an
effect on its expression. Minimal data are available on
signaling pathways regulating IRF-1 expression and/or
its nuclear translocation. Furthermore, in human kera-
tinocytes, blocking of the p38 signaling pathway was
described to reduce IFN-induced IRF-1 by half after 2
hours of stimulation (36). Blocking of the JAK/STAT-3
signaling pathway reduced TNF-induced IRF-1 expres-
sion in HUVECs (35).
IRF-1 and other members of the IRF family have
been reported to form dimers among themselves and
form complexes with other transcription factors, includ-
ing members of the NF-B signaling pathway (39). By
using immunoprecipitation, we established that IRF-1
was associated with NF-B and c-Jun in the nucleus,
confirming the presence of a complex combining IRF-1
with NF-B or c-Jun. This is consistent with a previous
report that NF-B can physically interact with IRF-1
(40) and can influence its binding to the basal transcrip-
tion complex. Previously, the function of IRF-1 has been
shown to be associated with NF-B p65 (41). Our data
confirmed that IRF-1 interacts with NF-B for nuclear
translocation in RASFs after TNF stimulation. How-
ever, the nuclear complex between IRF-1 and c-Jun has
not been described previously.
The next step was to use a functional assay to
confirm the role of IRF-1 in TNF-induced IL-18BP.
Our hypothesis was based on the fact that IL-18BP was
initially described as a key regulator of the Th1 immune
response. IL-18, as an important mediator of Th1 cell
differentiation, induces IFN production.
The biologic activities of cytokines are frequently
controlled by endogenous inhibitory proteins. IL-18 is
under the control of IL-18BP, and the result is IL-18
bioactivity. Thus, a negative feedback loop was de-
scribed, in which IL-18BP is the key mediator regulating
IL-18 bioactivity (42–45). However, to avoid premature
termination of IL-18 activity, induction of IL-18BP must
occur after a delay. Usually, IFN signals quickly
through the JAK/STAT signaling pathway (25). How-
ever, for this feedback loop and IL-18BP expression,
Figure 6. Blocking of IRF-1 regulates TNF-induced interleukin-18 (IL-18) bioactivity by reducing IL-18 binding protein a (IL-18BPa). RASFs
were transfected with control or IRF-1 small interfering RNA (siRNA) for 48 hours, using TransIT-TKO reagent. The transfected RASFs were
then stimulated with TNF (20 ng/ml). A, After 2 hours of TNF stimulation, the transfection efficiency was checked at the protein level. Results
are representative of 3 assays. B, After 48 hours of TNF stimulation, the amount of IL-18BPa was assessed at the protein level. C, IL-18 was
assessed at the mRNA level by real-time quantitative polymerase chain reaction, and its bioactivity was assessed using KG-1 cells. Bars show the
mean  SEM.   P  0.05. D, Schematic representation of the mechanism of TNF induction of IL-18 and IL-18BPa through IRF-1. TNF
induces IL-18BPa through IRF-1 nuclear translocation and regulates IL-18 bioactivity. See Figure 1 for other definitions.
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IFN required de novo synthesis of the transcription
factor IRF-1, which activates the IL-18BP promoter
(25). Because IRF-1 can bind to the IL-18BP promoter
and activate its transcription (40,41), we explored the
effect of IRF-1 knockdown on TNF-induced IL-18BP
expression in RASFs. We employed an approach using
siRNA to knock down IRF-1 expression. After confirm-
ing the reduction in IRF-1 at the protein level in the
presence of IRF-1 siRNA, we observed a reduction in
TNF-induced IL-18BPa at the protein level.
The second component of IL-18 bioactivity is
IL-18 itself. Because IL-18 levels are similar in the
presence or absence of the knockdown of IRF-1, IL-18
bioactivity was increased in the case of IRF-1 knock-
down. A discrepancy between antigenic protein and
functional bioactivity for TNF has been reported pre-
viously (46). This study is the first to show that IRF-1 is
a mediator of TNF-induced IL-18BPa. This concept
was previously described in various animal models in
vivo. Indeed, IRF-1–knockout mice have reduced or
undetectable expression of IL-18BP (25–27). In the
same mice, IL-18 expression was unaffected (27), sug-
gesting an increase in IL-18 bioactivity. However, the
IL-18 bioactivity in vivo was not examined in those
studies.
In this study, we showed that IRF-1 is a key
regulator of IL-18BPa expression in RASFs and can
thus regulate IL-18 bioactivity. Hence, strategies to
augment IRF-1 activity may be beneficial for the treat-
ment of RA.
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